Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Complete title: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer (GOG-0281)

Research Study Number GOG-0281
Principal Investigator Heidi Gray, MD
Phase II/III

Research Study Description

This randomized phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen citrate, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or topotecan hydrochloride in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number GOG-0281
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Gynecological Cancer; Ovarian Cancer; Solid Tumors; Neoplasms; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Cystadenocarcinoma; Genital Neoplasms, Female; Neoplasms, Cystic, Mucinous, and Serous; Endocrine Gland Neoplasms; Peritoneal Cancer; Adnexal Diseases; Gonadal Disorders; Endocrine System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials